This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

The new North Chicago facility, slated to open in 2027, will boost domestic production of key drug ingredients for immunology ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

Drugmaker AbbVie plans to construct a $195 million facility near its headquarters in North Chicago to manufacture active pharmaceutical ingredients, The Chicago Tribune reported Aug. 12. Construction ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie (NYSE: ABBV) has unveiled a $195 million investment to expand its North Chicago manufacturing plant to include domestic active pharmaceutical ingredient (API) production. The expansion is part ...

The global biopharma firm will build a new API production facility near its global headquarters in North Chicago.

"AbbVie expands North Chicago API production with $195m investment" was originally created and published by Pharmaceutical ...

AbbVie to invest $195m in US API manufacturing expansion as pharma rushes to boost domestic capacity ahead of expected drug ...

AbbVie continues to impress with its robust fundamentals, though it navigates through mixed market signals. All four analysts ...

AbbVie’s second quarter saw a significant positive market response, driven by robust sales from its immunology and ...

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...